Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Assouline

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Revue Neurologique|January 1, 1991
[Genetics of neurofibromatosis: recent progress and prospects]M Maillet-Vioud, S Narod, D Assouline, et al.
Cancer|September 26, 1997
Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte StudyC Fermé, Y Bastion, P Brice, et al.
Leukemia & Lymphoma|December 29, 1999
Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II studyA Belhabri, X Thomas, J Troncy, et al.
British Journal of Cancer|May 5, 2001
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyJ Y Douillard, D Lerouge, A Monnier, et al.
The New England Journal of Medicine|January 4, 1990
Leukemia following Hodgkin's diseaseJ M Kaldor, N E Day, E A Clarke, et al.
Transplantation|January 15, 1996
Hodgkin's disease after transplantationJ L Garnier, Y Lebranchu, J Dantal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 21, 2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMSR Houot, S Le Gouill, M Ojeda Uribe, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Revue Neurologique|January 1, 1991
[Genetics of neurofibromatosis: recent progress and prospects]M Maillet-Vioud, S Narod, D Assouline, et al.
Cancer|September 26, 1997
Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte StudyC Fermé, Y Bastion, P Brice, et al.
Leukemia & Lymphoma|December 29, 1999
Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II studyA Belhabri, X Thomas, J Troncy, et al.
British Journal of Cancer|May 5, 2001
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II studyJ Y Douillard, D Lerouge, A Monnier, et al.
The New England Journal of Medicine|January 4, 1990
Leukemia following Hodgkin's diseaseJ M Kaldor, N E Day, E A Clarke, et al.
Transplantation|January 15, 1996
Hodgkin's disease after transplantationJ L Garnier, Y Lebranchu, J Dantal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 21, 2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMSR Houot, S Le Gouill, M Ojeda Uribe, et al.
Pageof 2